No spam. Unsubscribe anytime.
HPLC Purity Analysis
Survodutide
CAS: 2805997-46-8
energy-balance research and metabolic research · NASH and liver fat reduction · Dual glucagon/GLP-1 receptor pharmacology
Survodutide is a dual glucagon/GLP-1 receptor agonist that combines GLP-1-mediated appetite suppression and insulin secretion with glucagon receptor-mediated increases in energy expenditure and hepatic fat oxidation.
- energy-balance research and metabolic research
- NASH and liver fat reduction
- Dual glucagon/GLP-1 receptor pharmacology
- Energy expenditure and metabolic rate studies
This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Frequently Bought Together
Bacteriostatic Water
Required for reconstitution
Semaglutide
GLP-1 / Weight Management
No spam. Unsubscribe anytime.
HPLC Purity Analysis
Specifications
How Survodutide Works
Survodutide is a dual glucagon/GLP-1 receptor agonist that combines GLP-1-mediated appetite suppression and insulin secretion with glucagon receptor-mediated increases in energy expenditure and hepatic fat oxidation. The glucagon component drives thermogenesis and lipolysis while the GLP-1 activity counterbalances any hyperglycemic effects of glucagon activation. This dual mechanism provides both metabolic research and liver fat reduction.
Research Applications
Pricing
| Size | Per Vial | 10-Pack |
|---|---|---|
10mg | $180.00 | $1800.00 |
10-pack pricing shown. Volume discounts for 50+ vials — contact us.
Certificate of Analysis
This COA is a representative sample. A batch-specific Certificate of Analysis with full HPLC chromatograms and mass spectrometry data is included with every order.
Research Use Only. This product is intended for laboratory research purposes only. Not for human consumption. Handle with appropriate safety precautions.
Related Peptides
Up to 50% OffSemaglutide
Clinically studied for steady weight reduction — once weekly
Up to 60% OffTirzepatide
The most studied dual-agonist for weight reduction
Up to 78% OffRetatrutide
Triple-receptor agonist studied for enhanced metabolic activity
Up to 38% OffLiraglutide
Daily GLP-1 studied for steady appetite regulation